GEN2 Directed Cancer Immunotherapy Trial
NCT04313868
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
61
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatocellular Carcinoma
Metastatic Cancer
Interventions
DRUG:
GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
Sponsor
GenVivo, Inc.